Taro Iwamoto

Taro Iwamoto serves as President and CEO of Otsuka Holdings, one of Japan's largest and most distinctive pharmaceutical and healthcare conglomerates. The Otsuka group is unusual in the global pharma industry for its combination of ethical pharmaceuticals, nutraceuticals, and consumer products — ranging from the blockbuster antipsychotic Abilify (aripiprazole) and its successor Rexulti (brexpiprazole) to Pocari Sweat, Japan's iconic sports drink, and Nature Made vitamins. The pharmaceutical business, operated primarily through Otsuka Pharmaceutical, is focused on psychiatry and neuroscience (where Abilify/Rexulti franchise generates billions in revenue), nephrology (tolvaptan for polycystic kidney disease), and oncology. The company's R&D approach is distinctively Japanese — prioritizing "creative" (Otsuka's word) science in underserved therapeutic areas rather than following the crowd into popular drug targets. This has produced both breakthrough successes and notable pipeline risks. Iwamoto's leadership challenges include managing the lifecycle transition from legacy products to next-generation compounds, expanding the global commercial footprint (particularly in the U.S. and Europe), and leveraging the stable cash flows from the consumer products division (Otsuka Foods, Pocari Sweat, and Tiovita nutritional drinks) to fund pharmaceutical R&D. The consumer business provides recession-resistant revenue that smooths the inherent volatility of drug development. Key stock drivers include psychiatric drug franchise growth, pipeline clinical trial results, the competitive landscape in neuroscience, and the cash generation profile of the consumer products segment.